ENTRECTINIB (has an active metabolite) | ENTRECTINIB | ATC L01EX14
ANTINEOPLASTIC A TROPOMYOSIN RECEPTOR TYROSINE KINASES INHIBITOR (TRK) TRKA, TRKB, AND TRKC PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS1 INHIBITOR ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR ALSO INHIBITS JAK2 AND TNK2 TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | ORAL | Cmax 3.13 MICROMOLAR Tmax 5 HOUR VD 551 LITER PPB 99 PERCENT Cl 19.6 LITER / HOUR HT 20 HOUR | TROPOMYOSIN RECEPTOR TYROSINE KINASES INHIBITOR (TRK) TRKA TRKB AND TRKC PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS1 ANAPLASTIC LYMPHOMA KINASE (ALK) PDB 5FTO (CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB) LIGAND CODE = YMX (link to the list of PDB complexes) Download experimental 3D coordinates of YMX with added hydrogens | High affinity nerve growth factor receptor UNIPROT P04629 NTRK1 -- ALK tyrosine kinase receptor UNIPROT Q9UM73 ALK more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |